Transcreener assays

High throughput tools to study thousands of target enzymes. Transcreener assays quantify ADP, AMP/GMP, UDP and GDP nucleotides as byproducts of common biological enzymatic reactions.

Dr Tobias Pusterla Dr Tobias Pusterla
International Marketing Manager, BMG LABTECH HQs
Dr Tobias Pusterla

Dr Tobias Pusterla

BMG LABTECH HQs

International Marketing Manager

linkedin-icon

About Dr Tobias Pusterla

Tobias Pusterla’s scientific background spans veterinary biotechnology, cancer cell biology, and the molecular mechanisms underlying inflammation‑driven tumorigenesis. After graduating in Veterinary Biotechnology at the University of Milan, Italy, he worked in mouse mutagenesis before completing a Ph.D. in Cellular and Molecular Biology through a joint program between the Open University of London, UK and the San Raffaele Scientific Institute, Milan, Italy. He later conducted postdoctoral research at the German Cancer Research Center (DKFZ) in Heidelberg, Germany, focusing on tumor biology, the tumor microenvironment, and the role of chronic inflammation in cancer development. His scientific work has contributed to understanding how damage‑associated molecular signals drive immune activation, cell migration, inflammation, and tumorigenesis, helping to clarify fundamental pathways linking cellular stress responses to physiological and pathological outcomes. After more than 13 years of research experience, he joined BMG LABTECH in 2013. Here, he oversees global marketing activities, including the creation of scientific content and the coordination of application support.

Areas of Expertise

  • Molecular biology
  • Cell biology
  • Cancer biology
  • Cell singaling
  • Tumor microenvronment

Academic Degrees

degree-icon
PhD in Cell and Molecular Biology Università Vita-Salute San Raffaele Milano and Open University
degree-icon
BSc Degree in Veterinary Biotechnlogy University of Milan

 

What are Transcreener Assays?

The universal Transcreener® assays from BellBrook Labs measure byproducts of common biological enzymatic reactions. Four competitive immunoassays for the direct detection of ADP, AMP/GMP, UDP, and GDP are available. Quantification of these nucleotides allows the calculation of enzymatic activity of e.g. kinases or methyltransferases. 

Transcreener assays rely on direct, highly-specific detection of nucleotides using antibodies that are able to differentiate between nucleotides on the basis of a single phosphate group. These assays can be used across entire families of nucleotide-dependent enzymes. The Transcreener assays use a homogenous, competitive immunoassay format in which the antibodies are paired with high-affinity fluorescent tracers. Displacement of the tracer by the nucleotide being detected causes a change in its fluorescence properties.

Versatile fluorescent detection

The Transcreener ADP2 kinase assay use far-red dyes and can be measured using three different fluorescent readouts:

1. Transcreener ADP2 FP assay

Fig. 1: Schematic of the Transcreener ADP2 FP assay

 

The Transcreener® ADP2 FP assay from BellBrook Labs is an extremely sensitive ADP assay with a more sensitive antibody against ADP, yielding an excellent signal at less than or equal to 10% ATP consumption for a broad range of initial ATP concentrations (0.1-1,000 μM). The result is the ability to screen low ATP Km enzymes and to use initial velocity enzyme kinetics at or below ATP Km concentrations, which leads to accurate inhibitor potencies and the ability to use less enzyme and substrate. Ratiometric, red-shifted fluorescence polarization output minimizes signal variability and reduces compound interference.

Fig. 2: Example of a Transcreener ADP2 FP assay

In step two the Transcreener ADP2 Detection Mixture, which contains an ADP Alexa633 tracer bound to an anti-ADP antibody, is added. If there is enzymatic activity resulting in necessary ADP then the bound tracer is displaced by the ADP. The free tracer rotates quickly leading to a lower polarization value. If there is no free ADP because of no enzymatic activity, the tracer is still bound to the antibody. This whole construct rotates very slowly giving a higher polarization number. Therefore, ADP production leads to a decrease in fluorescence polarization.

2. Transcreener ADP2 FI assay

Fig. 3: Schematic of the Transcreener ADP2 FI assay

The Transcreener® ADP2 Fluorescent Intensity (FI) assay from BellBrook Labs extends the Transcreener platform for ADP detection by utilizing a simple fluorescent intensity output which can be used on both fluorescence readers typically found in academic and therapeutic research labs (such as the CLARIOstar® and Omega series) as well as more complex plate readers more commonly used in core facilities and HTS labs (such as the PHERAstar® FSX)

Fig. 4: Performance (Z´ value) of PHERAstar and Omega readers with the Transcreener ADP2 FI assayThe Transcreener® ADP2 FI Assay is a red, competitive fluorescence intensity assay based on the detection of ADP and therefore is compatible with any enzyme class that produces ADP, including protein, lipid, and carbohydrate kinases, ATPases, DNA helicases, carboxylases, and glutamine synthetase. It is a simple one-step homogenous detection assay and is flexible with regard to ATP concentration (0.1 to 1,000 µM ATP). The assay provides an excellent signal at low substrate conversion, with a Z' ≥ 0.7 at 2.5% ATP conversion using 1 µM ATP.

3. Transcreener ADP2 TR-FRET assay

Fig. 5: Schematic of the Transcreener ADP2 TR-FRET assayThe Transcreener TR-FRET assays are a single-step, competitive immunoassay for direct detection of nucleotides with a far-red time-resolved Förster-resonance-energy-transfer (TR-FRET) readout. The reagents for all of the assays are a far-red tracer bound to a highly-specific monoclonal antibody-terbium conjugate. Excitation of the complex in the UV range (approx. 330 nm) results in energy transfer to the tracer and emission at a higher wavelength (665 nm) after a time delay. Nucleotide diphosphate or monophosphate produced by the target enzyme displaces the tracer from the antibody, leading to a decrease in TR-FRET. The use of a red tracer minimizes interference from fluorescent compounds and light scattering. The Transcreener TR-FRET assays are designed specifically for HTS with a single addition, mix-and-read format.

Fig. 6: Example of a Transcreener ADP2 TR-FRET assayA critical factor is the correct setup of the microplate reader used for data readout. Proper selection of filters, dichroics, gain, and flashes can impact the instrument`s sensitivity for any given assay. In order to validate an instrument for use with the Transcreener TR-FRET Assays, a Z' > 0.7 at 10% conversion of 10 μM ATP is required.

Certified instruments

Strict Transcreener validation criteria make sure that the detecting instrumentation fulfills all requirements in terms of performance (Assay Window and Z´value) and read times (a 384w microplate must be read < 5 min).

The BMG LABTECH microplate readers PHERAstar®FSX, CLARIOstar Plus, VANTAstar all achieved the Transcreener certification. The FLUOstar Omega is certified for the Transcreener ADP2 FI assay.

Meera Kumar from Bellbrook Labs says: "A Z` of 0.84 was obtained at 10% conversion when running a 10 μM ATP/ADP standard curve in FI format while the TR-FRET and FP format gave a Z` of 0.89 at 10% conversion when running a 10 μM ATP/ADP standard curve. We are proud to add the PHERAstar FSX to our growing list of Transcreener certified instruments."

Frequently asked questions

  • Why are microplate readers important for transcreener assays?

    Microplate readers facilitate rapid data collection across multiple samples simultaneously, significantly increasing throughput and reducing analysis time for transcreener assays.
  • What are Transcreener Assays and how are they used in research?

    Transcreener Assays are biochemical assays designed to measure enzyme activity, particularly kinase activity, by detecting specific molecular modifications. They are widely used in drug discovery and research to evaluate enzyme function and inhibition.
  • Can Transcreener Assays be used with cells or cell extracts?

    No, the assays are designed for use with purified target proteins. Cell lysates have mixtures of nucleotides and nucleotide metabolizing enzymes that will cause interference with the assays.
  • What types of enzymes can be measured using Transcreener Assays?

    Transcreener Assays primarily target kinases but can also be adapted for other enzymes that catalyze modifications detectable through fluorescence or other readouts.
  • How does the measurement process work in Transcreener Assays?

    The assay uses a fluorescent or luminescent detection method to quantify enzyme activity by measuring the conversion of substrates into products, providing real-time insights into enzymatic functions.
  • What are the advantages of using Transcreener Assays over traditional methods?

    They offer high sensitivity, specificity, and compatibility with high-throughput screening formats, enabling rapid and accurate assessment of enzyme activity in various samples.
  • Are Transcreener Assays suitable for use in high-throughput screening environments?

    Yes, they are specifically designed to be compatible with high-throughput screening, facilitating large-scale testing of compounds or conditions efficiently.
  • What is the typical workflow for conducting a Transcreener Assay?

    The workflow generally involves preparing samples with enzymes and substrates, incubating under optimal conditions, adding detection reagents, and measuring the signal using appropriate instrumentation.
  • What plate formats are recommended?

    Transcreener assays are commonly run in 384-well or 1536-well plates. Verify compatibility with your reader model and kit instructions.

Configure your microplate reader and get an initial recommendation!

Newsletter Sign-up